Literature DB >> 25098768

Matrix metalloproteinase inhibitors: a patent review (2011 - 2013).

Nian-Guang Li1, Yu-Ping Tang, Jin-Ao Duan, Zhi-Hao Shi.   

Abstract

INTRODUCTION: The MMPs are involved in tissue remodeling. An imbalance between the inhibition and activation of MMPs results in excessive degradation of the extracellular matrix, which leads to some diseases including cancer, rheumatoid arthritis, osteoarthritis, heart disease and neurodegenerative diseases such as stroke. In this review, recent advances in the research of MMP inhibitors are reviewed. AREAS COVERED: This updated review summarized new patents on MMP inhibitors within January 2011 - December 2013. EXPERT OPINION: This review gives the latest development in the area of MMP inhibitors, which aim to treat disease processes associated with the MMPs. Structure-based design techniques have been used successfully in the search of selective MMP inhibitors, and these inhibitors can also be derived from natural products. Furthermore, imaging 'in vivo' technologies have been developed in order to follow the drug distribution to the targeted tissues, and to quantify the drug efficiency.

Entities:  

Keywords:  MMPs; diagnostic imaging agents; drug design; inhibitor selectivity

Mesh:

Substances:

Year:  2014        PMID: 25098768     DOI: 10.1517/13543776.2014.937424

Source DB:  PubMed          Journal:  Expert Opin Ther Pat        ISSN: 1354-3776            Impact factor:   6.674


  7 in total

1.  The constitutive protease release by primary human acute myeloid leukemia cells.

Authors:  Maria Honnemyr; Øystein Bruserud; Annette K Brenner
Journal:  J Cancer Res Clin Oncol       Date:  2017-06-19       Impact factor: 4.553

2.  Sex-related differences in serum matrix metalloproteinase-9 screening non-calcified and mixed coronary atherosclerotic plaques in outpatients with chest pain.

Authors:  Chun Gu; Fang Wang; Zhihui Hou; Bin Lv; Yang Wang; Xiangfeng Cong; Xi Chen
Journal:  Heart Vessels       Date:  2017-07-19       Impact factor: 2.037

3.  Comparison of the Effects of Matrix Metalloproteinase Inhibitors on TNF-α Release from Activated Microglia and TNF-α Converting Enzyme Activity.

Authors:  Eun-Jung Lee; Pyong-Gon Moon; Moon-Chang Baek; Hee-Sun Kim
Journal:  Biomol Ther (Seoul)       Date:  2014-09-30       Impact factor: 4.634

4.  A matrix metalloproteinase inhibitor enhances anti-cytotoxic T lymphocyte antigen-4 antibody immunotherapy in breast cancer by reprogramming the tumor microenvironment.

Authors:  Mingyue Li; Shugang Xing; Haiying Zhang; Siqi Shang; Xiangxiang Li; Bo Ren; Gaiyun Li; Xiaona Chang; Yilei Li; Wei Li
Journal:  Oncol Rep       Date:  2016-01-05       Impact factor: 3.906

5.  Mercury based drug in ancient India: The red sulfide of mercury in nanoscale.

Authors:  Priyabrata Mukhi; Swapna Sarita Mohapatra; M Bhattacharjee; K K Ray; T S Muraleedharan; A Arun; R Sathyavathi; R R Juluri; P V Satyam; Alok K Panda; Ashis Biswas; S Nayak; Sreedhar Bojja; S Pratihar; Sujit Roy
Journal:  J Ayurveda Integr Med       Date:  2017-06-07

Review 6.  Extracellular Matrix Composition and Remodeling: Current Perspectives on Secondary Palate Formation, Cleft Lip/Palate, and Palatal Reconstruction.

Authors:  Katiúcia Batista Silva Paiva; Clara Soeiro Maas; Pâmella Monique Dos Santos; José Mauro Granjeiro; Ariadne Letra
Journal:  Front Cell Dev Biol       Date:  2019-12-13

7.  Bushenhuoxue formula attenuates cartilage degeneration in an osteoarthritic mouse model through TGF-β/MMP13 signaling.

Authors:  Ping-Er Wang; Lei Zhang; Jun Ying; Xing Jin; Cheng Luo; Shibing Xu; Rui Dong; Luwei Xiao; Peijian Tong; Hongting Jin
Journal:  J Transl Med       Date:  2018-03-20       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.